Merck
  • Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT.

Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT.

Veterinary and comparative oncology (2016-05-04)
L R Raposo, C Roma-Rodrigues, P Faísca, M Alves, J Henriques, M C Carvalheiro, M L Corvo, P V Baptista, A J Pombeiro, A R Fernandes
摘要

Here we describe the establishment of a new canine mammary tumour (CMT) cell line, FR37-CMT that does not show dependence on female hormonal signaling to induce tumour xenografts in NOD-SCID mice. FR37-CMT cell line has a stellate or fusiform shape, displays the ability to reorganize the collagen matrix, expresses vimentin, CD44 and shows the loss of E-cadherin which is considered a fundamental event in epithelial to mesenchymal transition (EMT). The up-regulation of ZEB1, the detection of phosphorylated ERK1/2 and the downregulation of DICER1 and miR-200c are also in accordance with the mesenchymal characteristics of FR37-CMT cell line. FR37-CMT shows a higher resistance to cisplatin (IC50 >50 µM) and to doxorubicin (IC50 >5.3 µM) compared with other CMT cell lines. These results support the use of FR37-CMT as a new CMT model that may assist the understanding of the molecular mechanisms underlying EMT, CMT drug resistance, fostering the development of novel therapies targeting CMT.

材料
货号
品牌
产品描述

Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid
Sigma-Aldrich
抗 波形蛋白抗体,小鼠单克隆 小鼠抗, clone V9, purified from hybridoma cell culture
Sigma-Aldrich
抗-HER2 兔抗, affinity isolated antibody
Sigma-Aldrich
Anti-Estrogen Receptor-α antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
抗VEpCAM ICD 抗体,小鼠单克隆, clone 4A7, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-CD44 antibody produced in mouse, clone 1E1, purified immunoglobulin, buffered aqueous solution